Literature DB >> 2649983

Ifosfamide--pharmacologic overview.

G Sarosy1.   

Abstract

Ifosfamide and its structural analogue cyclophosphamide are oxazaphosphorine nitrogen mustards, a group of compounds synthesized in West Germany more than 20 years ago. Whereas both chloroethyl groups of cyclophosphamide are attached to the same exocyclic nitrogen, one of ifosfamide's chloroethyl groups is attached to an endocyclic nitrogen. This minor structural change may account for the different pharmacologic behavior of these two compounds as well as their different spectrums of clinical activity and toxicity. Initial clinical trials of ifosfamide explored the use of a single intravenous dose. Hemorrhagic cystitis appeared to be dose-dependent and limited the use of this agent. However, the development of a systemic thiol uroprotector, such as mesna, has overcome this toxicity, permitting higher ifosfamide doses to be administered. Currently, ifosfamide is usually administered daily for five days in combination with mesna. The pharmacology and metabolism of ifosfamide may explain the toxicities associated with this compound and should be considered when designing schedules of administration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2649983

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  8 in total

Review 1.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 2.  Renal toxicity and chemotherapy in children with cancer.

Authors:  Antonio Ruggiero; Pietro Ferrara; Giorgio Attinà; Daniela Rizzo; Riccardo Riccardi
Journal:  Br J Clin Pharmacol       Date:  2017-09-20       Impact factor: 4.335

3.  Preclinical pharmacokinetics and stability of isophosphoramide mustard.

Authors:  J J Zheng; K K Chan; F Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 4.  Late effects on the urinary bladder in patients treated for cancer in childhood: a report from the Children's Oncology Group.

Authors:  Michael Ritchey; Fernando Ferrer; Patricia Shearer; Sheri L Spunt
Journal:  Pediatr Blood Cancer       Date:  2009-04       Impact factor: 3.167

5.  Ifosfamide-related encephalopathy in elderly patients : report of five cases and review of the literature.

Authors:  Antonella Brunello; Umberto Basso; Elena Rossi; Micaela Stefani; Cristina Ghiotto; Dario Marino; Gino Crivellari; Silvio Monfardini
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 6.  Ifosfamide pharmacokinetics.

Authors:  L D Lewis
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

7.  Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture.

Authors:  M Mohrmann; S Ansorge; U Schmich; B Schönfeld; M Brandis
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

8.  A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration.

Authors:  A Katz; S Epelman; A Anelli; E F Gorender; S M Cruz; R M Oliveira; L A Marques
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.